Safety and efficacy of a PD-1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers

Clinicians evaluated the safety and efficacy of combining a programmed cell death 1 (PD-1) inhibitor with oxaliplatin plus S-1 (SOX) for treating Borrmann large type III and IV gastric cancers. In this retrospective analysis involving 89 patients, those who received PD-1 combined with SOX (P-SOX) had a significantly higher pathological response rate (42.86% with tumor regression grade 0/1) compared to those who received only SOX. This suggests that a PD-1 inhibitor combined with SOX could improve tumor regression rates during neoadjuvant therapy for patients with advanced gastric cancers.